Filing Details
- Accession Number:
- 0001181431-14-008178
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-02-20 19:46:31
- Reporting Period:
- 2014-02-18
- Filing Date:
- 2014-02-20
- Accepted Time:
- 2014-02-20 19:46:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1497253 | Organovo Holdings Inc. | ONVO | Biological Products, (No Disgnostic Substances) (2836) | 271488943 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1536583 | Keith Murphy | 6275 Nancy Ridge Drive, Suite 110 San Diego CA 92121 | Chairman, Ceo And President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-02-18 | 100,000 | $9.82 | 5,974,643 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2014-02-19 | 50,000 | $0.00 | 6,024,643 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2014-02-19 | 27,307 | $9.86 | 5,997,336 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2014-02-19 | 27,307 | $0.00 | 27,307 | $9.86 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2014-02-19 | 550,000 | $0.00 | 550,000 | $9.86 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,307 | 2014-02-19 | 2024-02-19 | No | 4 | A | Direct |
| 550,000 | 2024-02-19 | No | 4 | A | Direct |
Footnotes
- The sale of shares was effecutated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $9.75 to $9.88. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- In August 2012, Mr. Murphy received a grant of performance-based restricted stock units for 200,000 shares of Issuer's common stock, with 25% of the shares vesting upon the achievement of each of four specific performance milestones prior to December 31, 2014. On February 19, 2014, the Compensation Committee of the Issuer's Board of Directors determined that, as a result of the Issuer obtaining analyst coverage for its common stock, Mr. Murphy had achieved the third of four performance milestones and had vested in an additional 50,000 shares.
- These shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of performance-based restricted stock units granted in August 2012.
- This number does not include 898,756 shares of common stock underlying oustanding options and 30,000 shares of common stock underlying warrants held by Mr. Murphy; post-transaction Mr. Murphy continues to beneficially own or have a right to acquire 6,926,092 shares of common stock.
- The option was automatically issued pursuant to the terms of the Reporting Person's Equity Incentive Award Agreement issued in August 2012.
- Annual long-term equity award approved by the Compensation Committee.
- 25% of the option shares vest and become exercisable on February 19, 2015 and the remaining shares vest in 12 equal quarterly installments thereafter.
Billionaire Hedge Funds
